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doi:10.1016/j.jtcvs.2003.11.020850 The Journal of Thoracic and CardioObjectives: Surgical staging and resection of lung cancer may be done as 1
operation (combined) or 2 (staged). This study evaluates the safety and efficiency of
these treatment strategies.
Methods: From 1998 to July 2001, 343 patients underwent bronchoscopy, medias-
tinoscopy, and thoracotomy without induction chemoradiotherapy by 3 surgeons.
Fifty-seven patients were staged and 286 combined. Staged patients had higher
clinical stage (P  .001). Propensity-matched groups were compared to adjust for
this and other differences. Factors associated with safety and efficiency were
identified by propensity-adjusted multivariable analysis.
Results: Mortality and morbidity were similar for both strategies. Efficiency, mea-
sured by shorter operative time (1.2 hours) and lower cost (25%), was better for
combined strategy (P  .001). Hospital stay was similar, but revenue was 12%
higher for the staged strategy (P  .001). In propensity-matched comparisons
excluding surgeon, results were similar to the above. Comparisons including sur-
geon demonstrated similar cost and revenue for both strategies. Increased mortality
and morbidity were associated only with patient and tumor characteristics: male
gender, worsening Eastern Cooperative Oncology Group performance status, and
increasing pathological node classification. All measures of efficiency worsened
with increasing pathological classifications. Staged strategy was associated with
increased operative time and revenue, while one surgeon and patient smoking
history were associated with increased hospital stay and costs.
Conclusions: The combined strategy provides efficient, safe health care for clini-
cally operable lung cancer patients, but it may not be as financially rewarding as the
staged strategy. Treatment strategy is only 1 of many determinants of efficiency.
Availability of accurate intraoperative frozen-section diagnosis ofregional lymph node metastases led to a strategy of combinedsurgical staging (bronchoscopy and mediastinoscopy) and resec-tion (thoracotomy) of lung cancer (combined).1 This contrastswith a strategy of separating surgical staging from resection as 2operations (staged). Heterogeneity of practice and a computerized
cost-accounting system afforded the opportunity to evaluate the safety and effi-
ciency of these 2 strategies.
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Patients
From January 1998 to July 2001, 343 patients underwent bron-
choscopy, mediastinoscopy, and thoracotomy for resection of lung
cancer. Patients were identified in the Thoracic Surgery Registry,
which is approved for research by the institutional review board.
Ninety-eight patients had bronchoscopy and mediastinoscopy
followed by thoracotomy as a second procedure (staged); of these,
41 received induction chemoradiotherapy prior to thoracotomy.
Three hundred nineteen patients were to have all procedures under
the same anesthetic (combined); of these, 297 received it, 286 as
sole therapy and 11 after induction chemoradiotherapy. Twenty-
two patients (6.9%) in the planned combined group had unsus-
pected mediastinal node metastases at mediastinoscopy and re-
ceived induction therapy.
A disproportionate number of patients received induction che-
moradiotherapy in the staged group (41 of 98, 42%) versus the
combined group (33 of 319, 10%), which could bias comparisons.
Because induction chemoradiotherapy is more prolonged, compli-
cated, and expensive than resection alone,2-4 the analyses concen-
trated on the 57 staged and 286 combined patients in whom
resection was the sole therapy. Patient, tumor, and operative char-
acteristics are listed in Appendix 1. Rationale for resection of
pathological stage III and IV lung cancers is presented in Appen-
dix 2.
Bronchoscopy, Mediastinoscopy, and Thoracotomy
Staged. Bronchoscopy and mediastinoscopy were outpatient
procedures in 54 patients (95%). Mediastinal nodes were histolog-
ically evaluated from paraffin-embedded specimens stained with
hematoxylin and eosin. Patients had thoracotomy after a median of
13 days. Epidural anesthesia was used in 52 patients (91%), with
the catheter placed prior to induction.
Combined. Two hundred eighty patients (98%) were admitted
the day of surgery; 6 (2%) were in-hospital. Bronchoscopy and
mediastinoscopy were performed, and mediastinal nodes were
analyzed by frozen section with hematoxylin and eosin staining.
Patients with no mediastinal node metastases underwent thoracot-
omy. Epidural anesthesia was used in 263 patients (92%).
Postoperative care was identical for both groups.
Safety
Mortality. Operative mortality was defined as death in-hospital
or within 30 days of operation.
Morbidity. Complications were classified as (1) pulmonary,
which included reintubation, pneumothorax, adult respiratory dis-
tress syndrome, atelectasis requiring bronchoscopy, pneumonia,
bronchopleural fistula, pulmonary embolism, and pleural effusion;
(2) cardiac, which included arrhythmia and myocardial infarction;
or (3) other, which included stroke, vocal cord paralysis, sepsis,
and bleeding.
Efficiency
Operative time. Duration of operation was calculated from
anesthesia induction until anesthesia ended. For staged, operative
time was the sum of both procedures.
Hospital stay. Total hospital stay was defined as time from
admission to discharge date.
The Journal of ThoraciCost. Direct technical costs were costs directly associated with
patient care, obtained from the hospital’s cost accounting system.
Costs included anesthesia, surgery, pathology, nursing (operating
room, intensive care unit, hospital, and rehabilitation), pharmacy,
radiology, and miscellaneous. Indirect costs and physician fees
were not included. Cost of staged was expressed as a percentage of
combined. For propensity-matched pairs (see following text), rel-
ative cost was the ratio for each matched pair. For overall data, all
combinations of patient pairs (n 16,302) were used and resulting
ratios summarized.
Revenue
Net revenue was payment expected, calculated as charges less
contractual insurance adjustments plus patient copay. Revenue of
staged was expressed as a percentage of combined.
Comparisons of Strategies
Unadjusted comparison. Patient characteristics, safety, and
efficiency were compared using the chi-square test for categorical
variables and appropriate t test, Wilcoxon rank-sum test, or Cox
proportional hazards test for continuous variables. All statistical
tests were 2-sided.
Propensity-based comparisons. Selection bias was addressed
by constructing propensity scores.5,6 The probability of undergo-
ing combined versus staged strategy (propensity score) was esti-
mated by logistic regression analysis incorporating 17 variables:
gender, age, prior cardiac surgery, prior cancer surgery, cardiac
comorbidity, diabetes, weight loss over prior 3 months, Eastern
Cooperative Oncology Group (ECOG) performance status, Amer-
ican Society of Anesthesia classification, clinical tumor (T), re-
gional node (N), and distant metastases (M) classifications, use of
positron-emission tomography (PET) scan, tissue diagnosis of
cancer, hemoglobin, creatinine, and percent predicted forced vital
capacity (FVC). Sporadic missing values were imputed by taking
the most frequent response category or averaging nonmissing
values for continuous variables (1 imputed value for diabetes, 3 for
tissue diagnosis, 4 for FVC). For each of the 57 staged patients, a
well-matched combined patient was sought by propensity score
matching.7
By comparison without surgeon, the above procedure yielded
54 well-matched pairs (Appendix 3). Surgeon was added to the
17-variable propensity model to yield a second propensity score.
Using this score, 44 well-matched pairs were identified (see Ap-
pendix 3).
Risk Factors Related to Safety and Efficiency
Safety. Multivariable logistic regression analysis was used to
identify risk factors for morbidity (including mortality) in all 343
patients. Variables considered included 18 used to develop the
propensity score plus treatment strategy, type of operation, medi-
astinal node dissection, tumor histology, number of satellite lung
lesions, pathological TNM classifications, pathological stage
grouping, and propensity score (surgeon included). Analyses in-
cluded treatment strategy and propensity score, irrespective of P
value. Results are summarized as parameter estimate and standard
error with corresponding odds ratio, 68% confidence limits, and P
value.
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were positively skewed, Cox proportional hazards modeling was
used to identify risk factors. For hospital stay, data of patients
dying in-hospital were included up to time of death, then censored.
Results
Comparison of Treatment Strategies
Safety. Operative mortality and morbidity were similar
for staged and combined strategies (Table 1).
Efficiency. Median operative time was less for the com-
bined strategy (Figure 1); median hospital stay was similar
(P .1). Median relative direct technical costs were greater
for staged in the unadjusted and propensity-based compar-
ison without surgeon (Figure 2, A). However, in the com-
parison with surgeon, costs were similar because combined
cost was 15% higher than in the non–surgeon-matched
group, and staged cost was 6% lower. Median net revenue
was higher for the staged strategy (Figure 2, B).
Risk Factors Related to Safety and Efficiency
Safety. Male gender, worsening ECOG performance
status, and increasing pathological N classification were
associated with increased mortality and morbidity (Table 2),
but treatment strategy, adjusted for these variables and
propensity score, was not (P  .17).
Efficiency. The staged strategy was associated with
longer operative time and increased revenue (propensity
score was associated with operative time, but is a surrogate
for 1 surgeon whose operative time was lower and who had
a preference for the combined strategy) (Table 3). Strategy
was not associated with hospital stay or cost; however,
another surgeon with a preference for the staged strategy
was associated with longer hospital stay and higher cost.
Discussion
Safety
Accurate staging of lung cancer determines treatment. Com-
TABLE 1. Comparison of early outcome in unadjusted and
Outcome
Unadjusted A
Staged
(n  57)
Combined
(n  286) P
Stag
(n 
No. % No. % No.
Mortality 1 1.8 6 2.1 .9 0
CL 0.2-5.9 1.2-3.4 0-3
Morbidity
All 16 28 85 30 .8 14
Pulmonary* 4 7.0 26 9.1 .6 3
Cardiac* 11† 19 51† 18 .8 10
Other* 5 8.8 20 7.0 .6 4
CL, 68% confidence limits.
*Not mutually exclusive.
†Sixty of the 62 experienced postoperative atrial arrhythmias; 3 experiencbining surgical staging and resection of lung cancer was
852 The Journal of Thoracic and Cardiovascular Surgery ● Marproposed soon after introduction of mediastinoscopy.8,9
However, it has not gained universal acceptance because of
concerns about safety and efficiency. This study demon-
strates comparable operative mortality and morbidity with
either a staged or combined strategy.
These results are typical of modern surgical out-
comes,10,11 with a 2% operative mortality and 29% preva-
lence of complications, with cardiac complications twice as
common as others. Patient and tumor characteristics, not
treatment strategy, were the only risk factors for adverse
early outcomes.
Efficiency
Efficiency is performing a task with minimum waste, ex-
pense, and unnecessary effort; an efficient treatment is one
with high output-to-input ratio. Thus, efficiency was char-
acterized by measurable quantities: operative time, hospital
stay, direct technical costs, and net revenue. The combined
strategy reduced operative time. Hospital stay was not in-
fluenced by strategy but by patient and tumor characteristics
and surgeon. A surgeon’s postoperative protocols and dis-
charge criteria determine hospital stay and have an impact
equal to that of other risk factors for longer stay.
Expenditure of effort is difficult to quantify; we chose
the surrogate direct cost. For the practice as a whole and for
equivalent patients, costs were less when the combined
strategy was used. However, propensity-matched compari-
sons and multivariable analyses demonstrated that a sur-
geon’s practice could negate cost savings of this strategy.
Cost inefficiencies include unnecessary use of expensive
equipment and supplies, inefficient use of operative time,
lack of discharge planning, and expensive idiosyncrasies. It
is also more costly to care for smokers or patients with
advanced-stage lung cancers.
Preoperative patient instruction and preparation can re-
duce cost. Reimbursement is not directly coupled with
ensity-matched groups, with and without surgeon
ed, without surgeon Adjusted, with surgeon
Combined
(n  54) P
Staged
(n  44)
Combined
(n  44) P
No. % No. % No. %
3 5.6 .08 0 0 0 0 —
2.4-11 0-4.3 0-4.3
18 33 .4 9 20 15 34 .15
8 15 .11 2 4.6 6 14 .14
9 17 .8 7 16 7 16 1.0
5 9.3 .7 1 2.3 4 9.1 .17
myocardial infarction, including 1 of the 60.prop
djust
ed
54)
%
0
.5
26
5.6
18
7.4
ed acosts, as demonstrated in this study. Payor algorithms vary.
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some payors, but as a single DRG by others. Therefore,
payor mix will dictate levels of reimbursement for each
strategy. Although reimbursement is increased for sicker
patients, in this study reimbursement algorithms did not
recognize efficient health care delivery.
Benefits and Disadvantages
From an institutional perspective, there is potential loss of
operating room time with the combined strategy in about
7% of clinically operable patients with lung cancer who
have a positive mediastinoscopy and do not proceed to
planned thoracotomy. This “unused” operating time may be
absorbed by unexpected needs such as unrealistically sched-
uled elective surgery, same-day elective surgery, and emer-
gency operations. Dynamic optimization of this fixed re-
source (operating room time) requires adding this “7%”
factor to the utilization equation.12-14
Despite similar mortality and morbidity, the staged strat-
egy exposes all patients to risks of 2 operations, and the
combined strategy exposes 7% of patients to an aborted
planned thoracotomy. A psychological benefit may be pro-
vided by prompt, same-day treatment decision offered by
the combined strategy. The patient care team treats the
patient only once; a surgeon can consolidate decision mak-
ing to 1 episode and can be assured that histologic infor-
mation is 99.4% accurate1 and mediastinoscopy 94% neg-
atively predictive; and optimal health care delivery is
facilitated by eliminating redundant services. Unfortunately,
reduction of costs may not be linked directly to increased
Figure 1. Comparison of cumulative operating time in unadjusted
and propensity-matched groups, with and without surgeon. Bar
represents median and crossbars represent 15th and 85th percen-
tiles. Min, Minutes.revenue.
The Journal of ThoraciA disadvantage of the combined strategy is that if it is
abandoned, epidural and Foley catheters are needlessly
placed, with their attendant risks and costs.
Limitations
This is a single-institution study and may not be generaliz-
able. It is limited by lack of randomization, which is pos-
sible despite inability to blind the team to strategy. Con-
temporary methods for generating quasi-randomized
comparison, as done in this study, are also limited by
inability to account for unrecorded variables and to separate
confounding between surgeon and strategy.5,6 For this rea-
son, we have emphasized that it is the combination of
surgical team and strategy that is evaluated in the propen-
sity-matched comparisons, without accounting for surgeon;
in the comparisons with surgeon incorporated in the pro-
Figure 2. Box and whiskers comparison of monetary measures of
efficiency in unadjusted and propensity-matched groups, with
and without surgeon, expressed as the ratio of staged to com-
bined strategies. Dashed horizontal line at 1.0 represents cost and
revenue of combined approach. Each box encompasses 70% of
the ratios; horizontal line within box represents median ratio;
whiskers extend below to 5th percentile and above to 95th
percentile of ratios. A, Direct technical cost. B, Revenue.pensity score, both matched comparison and propensity-
c and Cardiovascular Surgery ● Volume 127, Number 3 853
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the surgeon in the cost-benefit balance.
Requirements and Indications for Combined Strategy
The combined strategy requires accurate clinical staging.
Using history, physical examination, routine blood work,
TABLE 3. Incremental risk factors for decreased efficienc
Risk factor Estimate  SE
Temporal measures
Longer operative time*
Staged strategy 0.77 0.179
Propensity score† 0.094 0.034
Higher pT‡ 0.59 0.161
Higher pN§ 0.42 0.129
Longer hospital stay*
Combined strategy 0.199 0.184
Propensity score† 0.0138 0.033
Older age 0.127 0.058
Smoker 0.49 0.22
Higher pN¶ 0.22 0.095
Surgeon B 0.37 0.142
Monetary measures
Higher total direct costs*
Staged strategy 0.021 0.190
Propensity score† 0.0088 0.036
Smoker 0.63 0.22
Higher pT‡ 0.41 0.163
Higher pN§ 0.32 0.134
Surgeon B 0.30 0.138
Lower net revenue*
Combined strategy 0.42 0.183
Propensity score† 0.0075 0.032
Lower creatinine# 0.54 0.21
Lower pT‡ 0.50 0.164
CL, 68% confidence limits; HR, hazard ratio; SD, standard deviation; SE, s
*Negative estimates and hazard ratios less than 1.0 correspond to less d
†Per 10% increase in score.
‡pT3-4 vs pT1-2.
§pN1-2 vs pN0.
Per 10-year increase.
¶Per 1-level increase, pN0 to pN3.
#Per 1 mg  dL1 increase.
TABLE 2. Incremental risk factors for adverse early outco
Risk factor Estimate  SE
Combined strategy 0.57 0.41
Propensity score* 0.084 0.067
Male 0.72 0.26
Worse ECOG performance status 0.42 0.170
Higher pN† 0.55 0.18
Intercept 1.63 0.55
c-statistic .67
CL, 68% confidence limits; ECOG, Eastern Cooperative Oncology Group; O
*Per 10% increase in score.
†Per 1-level increase, pN0 to pN2.and computed tomography, but with minimal use of PET,
854 The Journal of Thoracic and Cardiovascular Surgery ● Maronly 7% of patients had unsuspected pN2 or pN3 disease
at mediastinoscopy. This strategy also requires rigorous
mediastinoscopy and accurate and efficient histologic
evaluation. In this study group, mediastinoscopy was
95% accurate, 75% sensitive, 100% specific, 100% pos-
itively predictive, and 94% negatively predictive (Appen-
HR CL P
0.46 0.39-0.55 .001
1.10 1.06-1.14 .006
0.56 0.47-0.65 .001
0.66 0.58-0.75 .001
0.82 0.68-0.98 .3
1.01 0.98-1.05 .7
0.88 0.83-0.93 .03
0.61 0.49-0.76 .03
0.80 0.73-0.88 .02
0.69 0.60-0.79 .008
0.98 0.68-1.42 .9
1.01 0.97-1.04 .8
0.53 0.42-0.66 .004
0.67 0.57-0.78 .01
0.72 0.63-0.83 .02
0.74 0.65-0.85 .03
1.52 1.27-1.83 .02
0.99 0.96-1.02 .8
0.58 0.48-0.71 .008
0.61 0.52-0.72 .002
rd error.
le outcome.
OR CL P
1.76 1.17-2.8 .17
0.92 0.86-0.98 .2
2.0 1.58-2.7 .006
1.52 1.29-1.80 .01
1.73 1.44-2.1 .003
ds ratio; SE, standard error.y
tanda
esirabmes
R, oddix 2). No frozen-section diagnosis was reversed by
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false-negative frozen section analysis occurred in 0.6%
of patients.1
Assuming these requirements for a combined strategy
are in place, any patient who is medically operable and has
clinical stage I or II non–small cell lung cancer should be
offered a combined strategy. If mediastinoscopy demon-
strates unanticipated mediastinal nodal metastases, this
strategy should be abandoned. Because there is an obliga-
tory waiting period during frozen-section analysis of sam-
pled mediastinal nodes, the potential time saving of the
combined strategy can be lost if this period is not used
preparing for thoracotomy or if frozen-section analysis is
inefficient.
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Discussion
Dr Bryan F. Meyers (St Louis, Mo). Congratulations on your
work. I learn something from every paper that comes out of the
Cleveland Clinic, and this one is no exception.
This isn’t really a question. It’s just a dart to harass you a little
bit and put you off guard. I would say that the safety issue on this
paper is sort of a null issue. I would conclude that it’s very safe to
have lung surgery at the Cleveland Clinic. You had only 7 deaths
among 343 patients, and you would probably need several thou-
sand patients to show a clinically meaningful difference in mor-
tality between 2 strategies, regardless of what those strategies were.
Furthermore, there are no logical or plausible events that would affect
the safety of the operation and that would be caused by breaking the
The Journal of Thoracibronchoscopy and the mediastinoscopy away from the thoracotomy.
It’s intuitively not plausible, and you don’t have the power to assess
safety. So why not just call this an efficiency paper, period?
Dr DeCamp. Dr Meyers, I appreciate that comment. I’m
officially off balance. I think in the early literature, when medias-
tinoscopy was introduced as a way of staging operable lung cancer,
there was an issue of safety of performing staging and resection all
as 1 procedure when the accuracy of frozen-section analysis was in
question. It clearly takes a longer operative time to do a combined
procedure. If you have an institution that can turn these frozen
sections around quickly, then the patient is asleep just a short time
longer and has less fluid infused. Early on, however, it was our
initial impression that some of the combined patients got a lot
more intraoperative fluid and perhaps had more pulmonary com-
plications. So we initially thought about looking at this, and we
had a hypothesis that perhaps there was a safety issue. We were
happy to see that there wasn’t.
It’s true that both anatomic lung resection and mediastinoscopy
are pretty safe in our hands and that the primary thrust of this work
is the economic analysis; nevertheless, the safety issues are im-
portant. The message to the surgeon is, as long as you can do them
both safely, you can do them at the same time or staged, whatever
you want.
Dr Meyers. You have chosen to limit your analysis to patients
who have had all 3 procedures: bronchoscopy, mediastinoscopy,
and thoracotomy. In the paper, 7% of the patients who were
intended to have bronchoscopy, mediastinoscopy, and thoracot-
omy had a positive mediastinoscopy and then were excluded from
the analysis. Because there was a tendency toward larger tumors in
the combined group, those patients probably had a higher rate of
positive mediastinoscopy. It seems like you have biased the anal-
ysis, because the bronchoscopy/mediastinoscopy, followed a week
later by thoracotomy, is a strategy that works out better in the case
of a positive mediastinoscopy: you are more efficient with oper-
ating time. In the combined plan, if you have a positive medias-
tinoscopy, you’re left with a hole in your operating schedule. So I
think you’ve biased the efficiency analysis a bit by including only
patients who had all 3 procedures and excluding the patients who
a stand-alone bronchoscopy.
Dr DeCamp. I would disagree with the suggestion that we
biased the analysis. Propensity matching is designed, in fact, to
correct selection bias. It is true that larger tumors are more likely
to have a positive mediastinoscopy. Those patients scheduled for
combined approach were clinically felt not to have N2 disease, but
7% of the time there were unexpected N2 nodes. Those patients
were excluded because when we get into the cost/revenue issue,
we wanted to avoid the morass of induction therapy and the
increasing costs related to that. So I think in terms of the actual
analysis, we’ve tried to make it as clean as we can. In the staged
bronchoscopy, mediastinoscopy, and thoracotomy group, the pos-
itive mediastinoscopies are also excluded from the cost/revenue
analysis because, again, we excluded patients who had advanced-
stage disease and who went off and had chemotherapy. So I think
the comparison is valid.
Your point is well taken that an unsuspected positive medias-
tinoscopy is an annoyance sometimes to the surgeon because
you’ve blocked 3 to 4 hours of time and what are you going to fill
that operating room time with? We try to make the point in the
c and Cardiovascular Surgery ● Volume 127, Number 3 855
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if you have an institution that has some flexibility and a reasonable
volume of unscheduled things that need to get done, you might be
able to make up that 7% time. If you’re in solo practice and your
next operative day is a week away, then this may not be a
particularly effective strategy.
Dr Meyers. You talked about the neatness of the analysis, and
it is neat and it’s very carefully and accurately done, but I just
wonder if all the propensity analysis and greedy matching and
balancing can overcome the skepticism that might be in the room.
If you just took the 44 patients per group that ended up in the
propensity-matched analysis and randomized them into 2 groups,
might you not have been able to have an actual clinical trial that
everybody could sink their teeth into?
Dr DeCamp. One of the conclusions that we draw from this
experience is that you could certainly do a prospective randomized
trial and try to tease apart what we’re trying to do retrospectively
with propensity matching. That’s one of the values of this kind of
statistical analysis. What we tried to show was that in my hands a
staged approach was cost effective and in my partner’s hands a
combined approach was cost effective as long as we applied our
own clinical judgment to the particular patient. I think we would
all agree that big tumors or big nodes are more likely to have
positive mediastinoscopies and are better approached in a staged
fashion.
Dr Michael T. Jaklitsch (Boston, Mass). I thought it was a
great presentation, and this analysis makes me comfortable with
your decision to do a combined approach. I do a staged approach.
But this analysis doesn’t convince me to abandon my way and
adopt a combined approach, because, again, it’s a point that Dr
Meyers already brought up: in this world of limited resources, my
personal most limited resource is operating room time. If I have to
block out thoracotomy time for every patient who is going for a
mediastinoscopy and it’s a negative mediastinoscopy, I’m going to
start pushing out my waiting time to 3 weeks, 4 weeks, and then
they are all going to see Dave Sugarbaker because he can get them
in quicker. The issue is that it is very predictable how long a
mediastinoscopy takes whether it’s going to be positive or negative
and it is very predictable how long a thoracotomy is going to take.
856 The Journal of Thoracic and Cardiovascular Surgery ● MarCombining the two injects doubt into my schedule. I am not
convinced that the combined approach suits my practice.
Dr Sugarbaker. Mike, do you have a question or just a
comment?
Dr Jaklitsch. A comment.
Dr DeCamp. Thank you, Dr Jaklitsch, for that insightful com-
ment. I want to make the point that this analysis in terms of cost
and revenue was done from the perspective of the hospital, not for
the surgeon. So your waiting time wasn’t given any monetary
value, I’m sorry to say, in this analysis.
Dr Mark J. Krasna (Baltimore, Md). I have a question actu-
ally relating to what we in Maryland call the BLT, and that is for
a left-sided tumor where you have a suspicion of an enlarged
aortopulmonary window node on computed tomography. In that
clinical scenario we have evolved the following sequence—a
bronchoscopy, mediastinoscopy, with Chamberlain/thoracosco-
py—at 1 sitting, and because that would be just too long to do
together, we would perform your thoracotomy the next week.
Some people advocate doing the bronchoscopy/mediastinoscopy at
1 sitting and then bringing the patient back for the thoracoscopy/
thoracotomy. I wonder if you have tried to do the bronchoscopy,
mediastinoscopy, left thoracoscopy, and lobectomy at the Cleve-
land Clinic, and how many of those can you get done in 1 day?
Dr DeCamp. I don’t have the data from this analysis to tell you
how many of these were left upper lobe tumors where that would
be a strategy that we would have to invoke. I can tell you that it’s
my practice to still do cervical and anterior mediastinoscopy for
left upper lobe tumors.
I occasionally approach staging left upper lobe disease with just
the video-thoracoscope and look at the aortopulmonary window
and make the leap of faith judgment that if there is no N2 disease
at levels 5 and 6, then there is not contralateral N3 disease. I don’t
think I’m speaking on my partner’s behalf in that regard.
Dr Krasna. Can you do that at the same time as the bronchos-
copy/mediastinoscopy/staging thoracoscopy?
Dr DeCamp. Yes, though sometimes I just do the thoracos-
copy and don’t do the mediastinoscopy for peripheral left upper
lobe T1 tumors.
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